Innovative program for palliative radiotherapy in Australia

Radiotherapy plays a significant role in the palliation of symptoms in patients with cancer. It can improve symptoms from bone metastases, spinal cord compression, superior vena cava obstruction and cerebral metastases. Long waiting lists and inconvenient access prolong suffering and may even discourage patients from utilising this service. With this in mind, a Rapid Response Palliative Radiotherapy Clinic was established at the Mater Centre – Radiation Oncology Services, Princess Alexandra Hospital in Brisbane. The study evaluates whether the clinic achieves its aim of providing timely and efficient palliative radiotherapy for oncology patients. Data were collected in the first 6 months of the clinic's operation and compared with data from palliative patients seen in other clinics at the same centre over the same period. Patients seen in the Rapid Response Clinic were more likely to have been treated within 24 h of being assessed, and were more likely to have received a single fraction treatment. The clinic fulfils the role of offering a timely and convenient radiation service for palliative patients and acts as a reference for other palliative radiotherapy services in Australia.     

Inhibin (10.7 kD prostatic peptide) in normal, hyperplastic, and malignant human endometria: an immunohistochemical study.

The expression of inhibin, a 10.7 kD follicle-stimulating hormone (FSH)-suppressing prostatic peptide of 94 amino acids, was investigated in normal human endometrium, endometrial hyperplasia, and adenocarcinoma, employing the avidin-biotin immunoperoxidase technique. The antiserum used was raised in rabbits against prostatic inhibin isolated from human seminal plasma. The study included 15 well differentiated, 32 moderately differentiated, and 21 poorly differentiated endometrial adenocarcinomas; 26 simple, five complex, and two complex atypical endometrial hyperplasias; and, for comparison, 25 normal proliferative and 30 normal secretory endometria. In malignant and hyperplastic endometrial tissues, inhibin was localized in the epithelial cytoplasm of endometrial glands while the stroma showed weak reactivity. On the other hand, inhibin was undetectable in the early proliferative phase, but was present on the luminal border of the glandular epithelium in the mid- and late proliferative phases. Secretory endometrium displayed strong inhibin reactivity in the cytoplasm of glandular epithelium and in the stroma. The increased inhibin reactivity in secretory endometrium as compared with the proliferative phase is indicative of a functional role for inhibin in the uterus. In addition, its localization in proliferative, hyperplastic, and malignant endometria suggests a possible regulatory role for inhibin in endometrial proliferation and growth.